SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry ($BB.TSX) is trending as investors anticipate upcoming earnings, with community members expressing optimism about QNX technology and its role in automotive and IoT sectors. Bullish sentiment is fueled by technical indicators, such as golden crosses and wedge formations, suggesting a potential breakout. Discussions also focus on future revenue and profitability, with some highlighting the company's strategic partnerships and potential for growth.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as the crypto community debates recent price dips and potential market direction, with some citing concerns over potential interest rate hikes and others viewing the pullback as a buying opportunity. Discussions range from identifying key support levels to speculation about whale activity and the influence of broader market trends. Overall, community sentiment is mixed, with both bullish and bearish outlooks being actively voiced.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending as traders discuss potential catalysts in the biotech sector, including AI applications in drug discovery and potential rate cuts. Community members are actively debating technical indicators and market sentiment, with some pointing to overbought conditions while others highlight bullish signals. Several AI-related partnerships and advancements within the biotech industry appear to be driving interest in LABU.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

The launch of the Bitwise XRP ETF, trading under the ticker TOXR, is driving much of the current conversation around XRP. Community members are debating the potential impact of the new ETF on XRP's price, analyzing technical charts, and discussing entry points. Some are optimistic about institutional adoption and a potential Christmas rally, while others express concerns about trading volume and regulatory hurdles.

Anheuser-Busch InBev SA/NV operates as a holding company, which engages in the manufacture and distribution of alcoholic and non-alcoholic beverages. It operates through the following geographical segments: North America, Middle Americas, South America, EMEA, Asia Pacific, and Global Export and Holding Companies. The company was founded on August 2, 1977 and is headquartered in Leuven, Belgium.

Anheuser-Busch InBev SA/NV - ADR

Anheuser-Busch InBev

Recent acquisitions, potential partnerships with cannabis companies, and digital transformations are driving conversation around $BUD, with some investors seeing it as undervalued. However, debate continues around the company's prior marketing decisions and their impact on market share, as well as broader trends in alcohol consumption and consumer preferences. Some analysts are downgrading the stock, while others are maintaining a positive outlook.

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Immunome Inc

IMNM is trending as investors digest news of upcoming Phase 3 data and recent business development activities, including acquisitions to bolster their antibody-drug conjugate capabilities. Community discussion revolves around the potential for a squeeze, with some expressing concern over the company's cash runway and others highlighting insider buying. The stock's volatility and upcoming data readouts are key points of interest for traders.

Equinox Gold Corp. is a growth-focused mining company, which engages in the exploration of gold mining properties. It operates through the following segments: Greenstone, Mesquite, Castle Mountain, Los Filos, Aurizona, Fazenda, RDM, Santa Luz, and Corporate. The company was founded by Marc Pais on March 23, 2007, and is headquartered in Vancouver, Canada.

Equinox Gold Corp

Equinox Gold is trending due to the announcement of selling its Brazil operations for over $1 billion, a move aimed at focusing on North American growth and generating significant upfront cash. The community is discussing the potential upside from this strategic shift, especially with the price of gold holding strong, and some are noting large call option purchases signaling bullish sentiment. Some analysts have also raised their price targets, adding to the positive momentum.

Stem, Inc. engages in the provision of an energy storage system, hardware, ongoing software platform and professional services, and solar asset performance monitoring and control. The company was founded in 2009 and is headquartered in Houston, TX.

Stem Inc - Ordinary Shares - Class A

Stem Inc

STEM is trending as investors discuss the company's potential restructuring of its professional services business and a recently announced deal, while also evaluating the implications of a new SEC filing. Community members are debating the company's revenue outlook and potential profitability, as well as technical indicators and possible trading strategies. The broader conversation encompasses the energy sector, the impact of partnerships, and the role of software in energy management.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as investors digest economic data and speculate on the Fed's next moves, particularly regarding rate cuts and a potential shift in leadership. Community discussions revolve around the impact of these factors on bond yields and the broader market, with some expressing concerns about inflation and the strength of the economic recovery. The ETF's performance is also influenced by global factors like the Bank of Japan's policy and trade dynamics.

Decentraland

Decentraland's MANA is trending as gaming tokens gain momentum, with community members actively discussing potential metaverse news and price predictions. The recent price action and strong volume have reignited interest, with some speculating about a run to previous all-time highs. There is optimism surrounding the broader gaming and metaverse sector, with some comparing MANA's potential to that of other cryptocurrencies that have experienced significant growth after ETF developments.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cannabis plants grow in the greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. (Photo by Drew Angerer/Getty Images)

Trump Moves A Step Closer To Reclassifying Marijuana As A Less Dangerous Drug — A Breakout Moment For Weed Industry?

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

Equity

<ul class="summary-bullets"><li>Bloomberg reported that the Centers for Medicare &amp; Medicaid Services (CMS), which runs the Medicare program, is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;</li><li>MSOS and YOLO, two key cannabis sector-focused funds, gained 3.4% and 2.7%, respectively.</li><li>The Trump administration seems to be backing cannabis as an industry, following its previous comments regarding CBD and reclassifying marijuana.</li></ul>Cannabis&nbsp;stocks advanced on Wednesday following a report speculating that certain U.S Medicare patients could soon be eligible to receive coverage for CBD under a new initiative.CBD, or cannabidiol, is a compound found in cannabis and used to treat sleep disorders, anxiety, pain, and inflammation. Some research suggests it may also treat cancer symptoms. The drug is sold as gummies, pet treats, and skincare supplements.<h2 class="st-heading-2">Cannabis Stocks Rally</h2>Tilray Brands’ shares rose 4.8%, while the over-the-counter stocks of Curaleaf Holdings, Trulieve Cannabis, and Green Thumb Industries gained between 2% to 5.6%. Shares of Innovative Industrial Properties, a real estate investment trust (REIT) that buys and leases specialized cannabis cultivation facilities, rose 1.1%.On Stocktwits, the retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/TLRY">TLRY</a> shifted to ‘extremely bullish’ from ‘bullish,’ while that for&nbsp;<a href="https://stocktwits.com/symbol/CURLF">CURLF</a> shifted to ‘bullish’ from ‘neutral.’ The sentiment was ‘bullish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">GTBIF</a>, and ‘bearish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">TCNNF</a> and&nbsp;<a href="https://stocktwits.com/symbol/IIPR">IIPR</a> as of the last reading.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF (MSOS)</a>, which tracks U.S. cannabis companies exclusively, and the&nbsp;<a href="https://stocktwits.com/symbol/YOLO">AdvisorShares Pure Cannabis ETF (YOLO)</a>, which also tracks overseas companies and cannabis-adjacent businesses, rose 3.4% and 2.7%, respectively.<h2 class="st-heading-2">CMS Initaitive</h2>The rally came after Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-26/medicare-to-test-making-cbd-treatment-available-for-seniors">reported</a> that the Centers for Medicare &amp; Medicaid Services (CMS) is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;Details of the proposed program aren’t available, but an early version of the plan focused on seniors in oncology and palliative care settings, according to a summary viewed by the news agency.Unnamed sources told Bloomberg that Howard Kessler, a payments financier who has advocated for expanded CBD access, met with Health and Human Services Secretary Robert F. Kennedy Jr. about the issue last month<h2 class="st-heading-2">A Trump Boost?</h2>The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. Hemp-derived cannabidiol (CBD) could "revolutionize senior healthcare" by slowing disease progression and serving as an alternative to prescription drugs, Trump had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-cannabis-stocks-lose-high-premarket-after-surge-triggered-by-trumps-post/chDDTJ9R3BB">said</a> in a video post in September.The previous month, Trump said his administration was weighing a move to reclassify marijuana as a less dangerous drug under federal law.That said, doubts over cannabis efficacy in healthcare remain. A&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836267">recent study</a> funded by the Food and Drug Administration suggested that prolonged use of CBD may cause liver toxicity, while other research suggests it can interfere with other medications, harm male reproductive health, and pose potential risks to children and pregnant women.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/holiday-shopping-could-soar-to-a-record-1-trillion-this-year-with-online-spending-blasting-to-new-highs/cL5eLqVREW6">Holiday Shopping Could Soar To A Record $1 Trillion This Year, With Online Spending Blasting To New Highs</a>

Tilray, IIPR, Trulieve, Other Cannabis Stocks Rally On Report Of Government Considering Adding CBD Treatment For Medicare Patients  

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. 

<ul class="summary-bullets"><li>The provision bans online, gas station, and corner store sales of intoxicating hemp products, including delta-8, starting in 2026.</li><li>The rules are set to take effect in 2026, creating new compliance requirements for producers and retailers.</li><li>Tilray criticized the legislation, warning that it may prompt consumers to turn to unregulated alternatives.</li></ul>Cannabis stocks were trading lower in afternoon trade on Thursday amid broader weakness in the equities market after the U.S. government funding bill to end the shutdown included language tightening rules on hemp-derived THC products.Tilray Brands (TLRY) and Canopy Growth (CGC) shares fell more than 7%, while Green Thumb Industries (GTBIF) dipped 2.4%. Retail sentiment was ‘bearish’ around&nbsp;<a href="https://stocktwits.com/symbol/TLRY">Tilray’s stock</a>, according to Stocktwits data.&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">Green Thumb Industries’ stock</a> saw retail sentiment trending in ‘bullish’ territory over the past day, while retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/CGC">Canopy Growth’s stock</a> trended in the ‘extremely bullish’ zone.<h2 class="st-heading-2">New Hemp Rules Take Effect in 2026</h2>The funding legislation includes a provision banning the “unregulated sale of intoxicating hemp-based or hemp-derived products, including delta-8, from being sold online, in gas stations, and corner stores,” according to a Senate Appropriations Committee summary. The rules are set to take effect in 2026, creating new compliance requirements for producers and retailers.Tilray criticized the move, calling it a “misguided” step that could push consumers toward unregulated alternatives. “Prohibition and overly restrictive measures do not work,” the company said in a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tilray.com/news-releases/news-release-details/tilray-brands-condemns-misguided-prohibitionist-measures-and">statement</a> on Wednesday.<h2 class="st-heading-2">Retail Traders See Upside</h2>One Stocktwits user noted that the federal hemp ban increases the upside and that it’s a good opportunity to buy the dip.<stembedurl>https://stocktwits.com/techvested/message/636064141</stembedurl>Another user highlighted the optimism of investors buying cheap shares, anticipating that a rescheduling announcement for cannabis may be on the horizon later this year or next year.&nbsp;<stembedurl>https://stocktwits.com/Thumbszilla/message/636090102</stembedurl>The regulatory changes also weighed on broader cannabis-focused exchange-traded funds. AdvisorShares Pure U.S. Cannabis ETF (<a href="https://stocktwits.com/symbol/MSOS">MSOS</a>) fell more than 5% in afternoon trade on Thursday, while the Cambria Cannabis ETF (<a href="https://stocktwits.com/symbol/TOKE">TOKE</a>) dropped 1.4%.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/circle-stock-gains-after-jpmorgan-turns-bullish-cathie-woods-ark-invest-buys-the-dip/cLP9RYgRE3X">Circle Stock Gains Pre-Market After JPMorgan Turns Bullish, Cathie Wood’s Ark Invest Buys The Dip</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cannabis Stocks Drop As Shutdown Deal Tightens Hemp-THC Rules

The U.S. government funding bill to end the shutdown included language tightening rules on hemp-derived THC products.

Trade War or Not, Specific Industry ETFs Are in Sweet Spots

Trade war jitters rise, but ETFs like MSOS, SILJ, SGDJ, BBC, WISE & CTEX shine on solid fundamentals, offering either safe havens or growth potential.

From Loss to Lift-Off: Marijuana ETFs Rebound on Legalization Prospects 

Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism. 

Best-Performing ETFs of Last Week

Despite the U.S. govt shutdown, ETFs like MSOS, WEED, HOOW, HYDR, BKCH & SATO surged last week, driven by rallies in cannabis, hydrogen & crypto.

Top-Performing ETF Areas of Q3

Small caps led Q3 gains, while other standout ETF areas are Bitcoin mining (WGMI, MNRS), cannabis (MSOS, WEED), Ethereum (ETH, ETHW) and rare earths (REMX).

5 Best-Performing Sector ETFs of August

Marijuana, crypto, materials, healthcare and space ETFs led August gains despite tech volatility. These ETFs are MSOS, REMX, IHF, UFO, and ETHW. 

Cannabis ETFs Soar as Trump Mulls Over Marijuana Reclassification

Cannabis ETFs like WEED, CNBS and MJ surge after Trump confirmed that his administration is weighing marijuana's move from Schedule I to Schedule III.


President Donald Trump confirmed on Monday that he is looking at reclassifying marijuana and may announce his final decision in the next few weeks. "We're looking at reclassification, and we'll make a determination over the next few weeks," Trump told reporters during a press conference about cracking down on crime in Washington, D.C.His comments come after The Wall Street Journal (WSJ)&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/politics/policy/trump-marijuana-federal-drug-classification-01a73b8c">reported</a> last week that Trump may be interested in changing the drug’s classification. Marijuana-linked stocks like Aurora Cannabis (ACB), Canopy Growth (CGC), Tilray Brands (TLRY), Cronos Group (CRON), and Trulieve Cannabis (TCNNF) were already rallying in pre-market trade on the report.&nbsp;They continued to rally after Trump’s confirmation, with&nbsp;<a href="http://stocktwits.com/symbol/CGC">Canopy Growth’s</a> stock surging nearly 30% in midday trade.&nbsp;<a href="http://stocktwits.com/symbol/TLRY">Tilray’s stock</a> jumped 22%, followed by&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="http://tcnnf">Trulieve’s stock</a> gaining more than 18%. Aurora Cannabis’s stock climbed 12.5% on Monday.On Stocktwits, retail sentiment around Canopy Growth moved higher within ‘extremely bullish’ territory amid ‘extremely high’ levels of chatter. Meanwhile, retail sentiment around Tilray Brands improved to ‘bullish’ from ‘bearish’ a day ago, and retail sentiment around Trulieve was moved higher within ‘extremely bullish’ territory.“Some people like it. Some people hate it. Some people hate the whole concept of marijuana, because if it’s bad for the children, it’s bad for people older than children,” the President said, noting that medical marijuana, specifically, may hold benefits.&nbsp;“I’ve heard great things to do with medical, and I’ve heard bad things having to do with just about everything else but medical,” he said.Reclassification of marijuana from a Schedule I drug to a Schedule III drug would ease restrictions, allow tax breaks, and expand medical research.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-declares-liberation-day-in-dc-pushes-takeover-of-city-police/chrHGOoRdee">Trump Declares ‘Liberation Day’ in DC, Pushes Takeover Of City Police</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions during a press conference in the James S. Brady Press Briefing Room of the White House August 11, 2025 in Washington, DC. (Photo by Andrew Harnik/Getty Images)

Trump Confirms Marijuana Reclassification Decision To Be Made In ‘Next Few Weeks’ 

The President noted that there’s a difference of opinion on the benefits of marijuana, but added that he’s heard “great things” with respect to medical marijuana, specifically.

MSOS
AdvisorShares Pure US Cannabis ETF

Feed

News

Sentiment

Fundamentals

Info

Latest MSOS News

MSOSAdvisorShares Pure US Cannabis ETF